[시장보고서]세계의 생세포 이미징 시장(-2030년) : 제품(장치, 소모품, 소프트웨어 및 서비스), 용도(세포 생물학, 줄기 세포, 창약), 기술(타임랩스 현미경, FRET, FRAP, HCS), 최종사용자(제약 및 바이오테크놀러지, CRO)

세계의 생세포 이미징 시장(-2030년) : 제품(장치, 소모품, 소프트웨어 및 서비스), 용도(세포 생물학, 줄기 세포, 창약), 기술(타임랩스 현미경, FRET, FRAP, HCS), 최종사용자(제약 및 바이오테크놀러지, CRO)

Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services), Application (Cell Biology, Stem Cells, Drug Discovery), Technology (Time-lapse Microscopy, FRET, FRAP, HCS), End User (Pharma, Biotech, CROs) - Global Forecast to 2030

상품코드 : 1718868 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 04월

페이지 정보 : 영문 377 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 6,991,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,393,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,511,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,125,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 생세포 이미징 시장 규모는 2025년 31억 3,000만 달러에서 예측 기간 동안 CAGR 8.68%로 추이하고, 2030년에는 47억 5,000만 달러에 달할 것으로 예측되고 있습니다.

이미징 기술의 지속적인 진보와 세계적인 암 증례 증가가 이 시장의 성장을 지원하는 요인이 되고 있습니다. 기업은 생세포 이미징 분야에서 새로운 성장 기회를 획득하기 위해 신흥 시장에의 전개를 진행하고 있지만, 기기의 고비용이 이 전개를 제한하고 있어, 이러한 제품은 소규모 학술 기관이나 제약회사에게 손이 닿기 어려운 상황이 되고 있습니다.

조사 범위
조사 대상 연도	2024-2030년
기준연도	2024년
예측 기간	2024-2030년
단위	금액(달러)
부문	제품, 기술, 용도, 최종 사용자
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

제공 구분별로는 분석 소프트웨어의 부문이 예측 기간 중에 최대의 성장이 예상되고 있습니다. 기술이 고도화됨에 따라 연구자들은 방대하고 복잡한 이미지 데이터를 관리하고 실시간으로 분석하고 생물학적으로 유의한 지식을 추출하기 위한 강력한 소프트웨어 툴이 필요합니다. 3D 이미징, 타임랩스 현미경의 보급도 다차원 데이터 세트에 대응할 수 있는 인텔리전트 소프트웨어 수요를 더욱 밀어 올리고 있습니다. 세포의 세분화(영역 분할), 트래킹, 페노타이핑(표현형의 해석)이 보다 신속하고 정확하게 실시할 수 있게 되어, 이러한 툴은 창약, 암 연구, 재생 의료에 있어서 필수적인 존재가 되고 있습니다.

최종 사용자별로는 제약 및 바이오테크놀러지 기업이 2024년에 가장 큰 점유율을 차지했습니다. 만성 질환 증가나 정확한 치료에 대한 요구의 고조가, 이러한 분야에서의 생세포 이미징 기술의 채용을 한층 더 밀고 있습니다.

지역별로는 아시아태평양이 가장 급성장하고 있는 지역이며, 예측 기간 중에는 최대의 CAGR을 보여줄 전망입니다. 인도에서는 연구개발 활동이 활발해지고 있으며, 특히 창약과 재생의료에서는 고도의 이미징 기술이 필요합니다.

본 보고서에서는 세계 생세포 이미징 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 기술 및 특허 동향, 법규제 환경, 사례 연구, 시장 규모 추이와 예측, 각종 구분 및 지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 과제
고객의 사업에 영향을 주는 동향/혁신
가격 분석
밸류체인 분석
생태계 분석
투자 및 자금 조달 활동
기술 분석
특허 분석
무역 데이터 분석
주요 회의 및 이벤트
규제 상황
Porter's Five Forces 분석
주요 이해관계자와 구매 기준
AI/생성형 AI가 생세포 이미징 시장에 미치는 영향
2025년 미국 관세가 생세포 이미징 시장에 미치는 영향

제6장 생세포 이미징 시장 : 제공 내용별

제품
- 기기
- 소모품
소프트웨어
서비스

제7장 생세포 이미징 시장 : 기술별

타임랩스 현미경
형광 공명 에너지 이동
광퇴색 후의 형광 회복
하이 컨텐츠 스크리닝
기타

제8장 생세포 이미징 시장 : 용도별

세포 생물학 연구
창약
줄기세포 연구
발생 생물학 연구

제9장 생세포 이미징 시장 : 최종 사용자별

제약 및 바이오테크놀러지 기업
학술연구기관
CRO

제10장 생세포 이미징 시장 : 지역별

북미
- 거시경제 분석
- 미국
- 캐나다
유럽
- 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
아시아태평양
- 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타
라틴아메리카
- 거시경제 전망
- 브라질
- 멕시코
- 기타
중동
- 거시경제 전망
- GCC 국가
- 기타
아프리카
- 거시경제 전망

제11장 경쟁 구도

주요 기업의 전략/유력 기업
수익 분석
시장 점유율 분석
기업평가와 재무지표
브랜드/제품 비교
기업 평가 매트릭스 : 주요 기업
주요 기업의 기업 실적
기업평가 매트릭스: 스타트업/중소기업
경쟁 벤치마킹: 스타트업/중소기업
경쟁 시나리오

제12장 기업 프로파일

주요 기업
- DANAHER
- ZEISS GROUP
- THERMO FISHER SCIENTIFIC INC.
- REVVITY
- SARTORIUS AG
- NIKON CORPORATION
- EVIDENT
- AGILENT TECHNOLOGIES, INC.
- NANOENTEK
- BRUKER
- BD
- MERCK KGAA
- BIO-RAD LABORATORIES, INC.
- TECAN TRADING AG
- SYSMEX CORPORATION
- CORNING INCORPORATED
기타 기업
- AXION BIOSYSTEMS, INC.
- BLUE-RAY BIOTECH CORP.
- CURIOSIS INC.
- CYTENA GMBH
- ABBERIOR GMBH
- PHASE HOLOGRAPHIC IMAGING PHI AB
- ALIGNED GENETICS INC.
- CHERRY BIOTECH
- NANOLIVE SA
- CYTOTRONICS
- ETALUMA, INC.
- TISSUEGNOSTICS GMBH

제13장 부록

JHS

영문 목차

영문목차

The global live cell imaging market is projected to reach USD 4.75 billion in 2030 from USD 3.13 billion in 2025, growing at a CAGR of 8.68% during the forecast period. Ongoing advancements in imaging technologies, along with the rising cancer cases in the world, are factors supporting the growth of the market. Moreover, the availability of funds and grants for cellular biology research and the growing adoption of HCS techniques for drug discovery and research is increasing the demand for live cell imaging products and consumables, supporting the growth of the market. Key players are expanding their reach in emerging markets to grab new growth opportunities in the field of live cell imaging; however, this expansion is restricted due to the high cost of live cell imaging instruments, making these products inaccessible to small academic institutes and pharmaceutical companies.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Offerings, Technology, Application, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The market for live cell imaging and analysis software is expected to witness the highest growth within the offerings segment during the forecast period.

The live cell imaging software market is expected to witness the highest growth during the forecast period within the offering segment. This high growth can be attributed to the growing demand for advanced data analysis, automation, and AI integration in cellular research. As imaging technologies become more advanced, researchers require powerful software tools to manage large volumes of complex image data, perform real-time analysis, and extract meaningful biological insights. The growing adoption of high-content screening, 3D imaging, and time-lapse microscopy further fuels the need for intelligent software capable of handling multi-dimensional datasets. In addition, the integration of machine learning and deep learning algorithms into imaging software is enabling faster and more accurate cell segmentation, tracking, and phenotyping, making these tools essential in drug discovery, cancer research, and regenerative medicine.

The pharmaceutical & biotechnology companies end user segment held the largest market share in the live cell imaging market, by end user, during the forecast period.

Pharmaceutical & biotechnology companies held the largest share of the live cell imaging market by end users in 2024. This large share can be attributed to the increasing demand for advanced imaging technologies in drug discovery, cell biology research, and personalized medicine. These companies heavily rely on live cell imaging to observe cellular behaviors, study disease mechanisms, and evaluate the effects of potential drug candidates in real time. The rise in the prevalence of chronic diseases and the growing need for precise therapies further fuel the adoption of live cell imaging technologies in these sectors. This trend is expected to continue during the forecast period of 2025-2030, driven by ongoing innovations in imaging technologies, the need for faster and more accurate drug development, and the growing importance of cellular research in therapeutic development.

Asia Pacific is expected to be the fastest-growing region in the live cell imaging market.

Asia Pacific is the fastest-growing region in the live cell imaging market, having the highest CAGR during the forecast period of 2025-2030. This growth is driven by increased investment in the healthcare and biotechnology sectors, along with the rising demand for advanced imaging technologies. China, Japan, and India are increasing their research and development activities, particularly in drug discovery and regenerative medicine, which require advanced imaging techniques. Additionally, government support for scientific research and the expanding focus on personalized medicine are key factors fueling this market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

List of Companies Profiled in the Report:

Danaher (US)
Zeiss Group (Germany)
Nikon Corporation (Japan)
Evident (Japan)
Revvity (US)
Sartorius AG (Germany)
Agilent Technologies, Inc. (US)
Thermo Fisher Scientific Inc. (US)
Nanoentek (Korea)
Bruker (US)
BD (US)
Merck KGaA (Germany)
Bio-Rad Laboratories, Inc. (US)
Tecan Trading AG (Switzerland)
Corning Incorporated (US)
Sysmex Corporation (Japan)
Blue-Ray Biotech Corp. (Taiwan)
Curiosis Inc. (South Korea)
CYTENA GmbH (Germany)
Abberior Instruments America LLC (Germany)
Phase Holographic Imaging PHI AB (Sweden)
Aligned Genetics (South Korea)
Cherry Biotech (France)
Nanolive SA (Switzerland)
CytoTronics (US)
Etaluma, Inc. (US)
Axion BioSystems, Inc (US)
TissueGnostics GmbH (Austria)

Research Coverage:

This report provides a detailed picture of the global live cell imaging market. It aims to estimate the size and future growth potential of the market across different segments such as the offering, technology, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the live cell imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the live cell imaging market. Competitive analysis of upcoming startups in the live cell imaging market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall live cell imaging market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (Growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, Growing availability of funds for research, advancement in imaging technology), restraints (High cost of high-content screening systems), opportunities (increasing adoption of live cell imaging technologies in emerging markets, and application of HCS in personalized medicine), and challenges (maintaining cell viability and cellular environment in cell cultures, and image analysis and data management) influencing the growth of the live cell imaging market
Product Development/Innovation: Detailed insight into newly launched products & services and technological assessment of the live cell imaging market
Market Development: Comprehensive information about lucrative markets - the report analyses the live cell imaging market across varied regions.
Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the live cell imaging market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and products and service offerings of leading players Danaher (US), Zeiss Group (Germany), Nikon Corporation (Japan), Evident (Japan), Revvity (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Nanoentek (Korea), Bruker (US), BD (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Corning Incorporated (US), Sysmex Corporation (Japan), Blue-Ray Biotech Corp. (Taiwan), Curiosis Inc. (South Korea), CYTENA GmbH (Germany), Abberior Instruments America LLC (Germany), Phase Holographic Imaging PHI AB (Sweden), Aligned Genetics (South Korea), Cherry Biotech (France), Nanolive SA (Switzerland), CytoTronics (US), Etaluma, Inc. (US), Axion BioSystems, Inc (US), and TissueGnostics GmbH (Austria) among others in the market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
- 2.2.1 INSIGHTS FROM PRIMARIES
- 2.2.2 TOP-DOWN APPROACH
2.3 GROWTH RATE FORECAST
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 LIVE CELL IMAGING MARKET OVERVIEW
4.2 NORTH AMERICA: LIVE CELL IMAGING MARKET, BY OFFERING AND COUNTRY, 2024
4.3 LIVE CELL IMAGING MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
4.4 LIVE CELL IMAGING MARKET, BY END USER, 2024
4.5 LIVE CELL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Growing adoption of high-content screening techniques in drug discovery
  - 5.2.1.2 Rising incidence of cancer
  - 5.2.1.3 Growing availability of research funds
  - 5.2.1.4 Advancements in imaging technology
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Expensive high-content screening systems
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Increasing adoption of live cell imaging technologies in emerging markets
  - 5.2.3.2 Growing applications of live cell imaging in personalized medicine
- 5.2.4 CHALLENGES
  - 5.2.4.1 Maintenance of cell viability and cellular environment in cell cultures
  - 5.2.4.2 Image analysis and data management
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 5.4.2 AVERAGE SELLING PRICE, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 INVESTMENT AND FUNDING ACTIVITY
5.8 TECHNOLOGY ANALYSIS
- 5.8.1 KEY TECHNOLOGIES
  - 5.8.1.1 Fluorescence microscopy
  - 5.8.1.2 Confocal microscopy
  - 5.8.1.3 Super-resolution microscopy
  - 5.8.1.4 Forster resonance energy transfer
  - 5.8.1.5 Fluorescence recovery after photobleaching
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
  - 5.8.2.1 Image analysis software
  - 5.8.2.2 Microfluidics
  - 5.8.2.3 Optogenetics
  - 5.8.2.4 Multiphoton microscopy
- 5.8.3 ADJACENT TECHNOLOGIES
  - 5.8.3.1 Fixed cell imaging
5.9 PATENT ANALYSIS
5.10 TRADE DATA ANALYSIS
- 5.10.1 IMPORT DATA FOR HS CODE 901120
- 5.10.2 EXPORT DATA FOR HS CODE 901120
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 REGULATORY LANDSCAPE
- 5.12.1 REGULATORY FRAMEWORK
  - 5.12.1.1 North America
    - 5.12.1.1.1 US
    - 5.12.1.1.2 Canada
  - 5.12.1.2 Europe
    - 5.12.1.2.1 UK
    - 5.12.1.2.2 European Union
  - 5.12.1.3 Asia Pacific
    - 5.12.1.3.1 Japan
    - 5.12.1.3.2 South Korea
    - 5.12.1.3.3 China
- 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 THREAT FROM NEW ENTRANTS
- 5.13.2 THREAT FROM SUBSTITUTES
- 5.13.3 BARGAINING POWER OF SUPPLIERS
- 5.13.4 BARGAINING POWER OF BUYERS
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
5.15 IMPACT OF AI/GENERATIVE AI ON LIVE CELL IMAGING MARKET
- 5.15.1 INTRODUCTION
- 5.15.2 KEY COMPANIES IMPLEMENTING AI
- 5.15.3 AI USE CASES
- 5.15.4 FUTURE OF AI IN LIVE CELL IMAGING ECOSYSTEM
5.16 IMPACT OF 2025 US TARIFF ON LIVE CELL IMAGING MARKET
- 5.16.1 INTRODUCTION
- 5.16.2 KEY TARIFF RATES
- 5.16.3 PRICE IMPACT ANALYSIS
- 5.16.4 IMPACT ON COUNTRY/REGION
  - 5.16.4.1 US
  - 5.16.4.2 Europe
  - 5.16.4.3 Asia Pacific
- 5.16.5 IMPACT ON END-USE INDUSTRIES
  - 5.16.5.1 Pharmaceutical & biotech companies
  - 5.16.5.2 Academic & research institutes
  - 5.16.5.3 Contract research organizations

6 LIVE CELL IMAGING MARKET, BY OFFERING

6.1 INTRODUCTION
6.2 PRODUCTS
- 6.2.1 INSTRUMENTS
  - 6.2.1.1 Microscopes
    - 6.2.1.1.1 Ongoing technological advancements in microscopes to support growth
  - 6.2.1.2 Cell imaging systems
    - 6.2.1.2.1 Seamless integration and workflow efficiency of standalone systems to boost market
  - 6.2.1.3 Cell analyzers
    - 6.2.1.3.1 Accuracy and reproducibility of cell analyzers to encourage growth
  - 6.2.1.4 Accessories
    - 6.2.1.4.1 Increasing demand for live cell imaging in life science research to accelerate growth
- 6.2.2 CONSUMABLES
  - 6.2.2.1 Reagents
    - 6.2.2.1.1 Widespread usage of reagents in life science research to foster growth
  - 6.2.2.2 Assay kits
    - 6.2.2.2.1 Higher customer convenience and time-saving solutions to amplify growth
  - 6.2.2.3 Media
    - 6.2.2.3.1 Increasing investments in cell-based research to intensify growth
  - 6.2.2.4 Other consumables
6.3 SOFTWARE
- 6.3.1 INCREASING ADVANCEMENTS IN IMAGE ACQUISITION TO SUPPORT GROWTH
6.4 SERVICES
- 6.4.1 GROWING DEMAND FOR OUTSOURCED EXPERTISE AND SPECIALIZED SERVICES TO FUEL MARKET

7 LIVE CELL IMAGING MARKET, BY TECHNOLOGY

7.1 INTRODUCTION
7.2 TIME-LAPSE MICROSCOPY
- 7.2.1 GROWING DEMAND FOR HIGH CONTENT AND HIGH THROUGHPUT ANALYSIS IN PRECLINICAL STUDIES TO DRIVE MARKET
7.3 FLUORESCENCE RESONANCE ENERGY TRANSFER
- 7.3.1 ADVANCEMENTS IN FLUORESCENT MATERIALS AND PROBES TO BOOST MARKET
7.4 FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING
- 7.4.1 INCREASING ADVANCEMENTS IN FLUORESCENT PROTEINS TO SPUR GROWTH
7.5 HIGH-CONTENT SCREENING
- 7.5.1 GROWING FOCUS ON DRUG DISCOVERY AND TOXICITY SCREENING TO DRIVE MARKET
7.6 OTHER TECHNOLOGIES

8 LIVE CELL IMAGING MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 CELL BIOLOGY RESEARCH
- 8.2.1 INCREASING FOCUS ON DISEASE RESEARCH TO SUPPORT GROWTH
8.3 DRUG DISCOVERY
- 8.3.1 GROWING USE OF HIGH-CONTENT SCREENING CELL-BASED ASSAYS IN DRUG DISCOVERY STUDIES TO BOOST MARKET
8.4 STEM CELL RESEARCH
- 8.4.1 INCREASING FOCUS ON REGENERATIVE MEDICINE TO EXPEDITE GROWTH
8.5 DEVELOPMENTAL BIOLOGY
- 8.5.1 RISING INTEREST IN ORGANOGENESIS AND TISSUE MORPHOGENESIS TO PROMOTE GROWTH

9 LIVE CELL IMAGING MARKET, BY END USER

9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 INCREASING R&D ACTIVITIES TO DEVELOP NEW DRUGS TO SUPPORT GROWTH
9.3 ACADEMIC & RESEARCH INSTITUTES
- 9.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH PROGRAMS TO AID GROWTH
9.4 CONTRACT RESEARCH ORGANIZATIONS
- 9.4.1 GROWING OUTSOURCING OF R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET

10 LIVE CELL IMAGING MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
- 10.2.2 US
  - 10.2.2.1 Presence of major players and increasing investments in life science research to sustain growth
- 10.2.3 CANADA
  - 10.2.3.1 Government initiatives to promote research to aid growth
10.3 EUROPE
- 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
- 10.3.2 GERMANY
  - 10.3.2.1 Presence of large number of academic research institutes to boost market
- 10.3.3 UK
  - 10.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to foster market
- 10.3.4 FRANCE
  - 10.3.4.1 Booming pharmaceutical manufacturing industry to drive market growth
- 10.3.5 ITALY
  - 10.3.5.1 Strong research tradition, government funding, and collaborative research networks to fuel growth
- 10.3.6 SPAIN
  - 10.3.6.1 Rising R&D expenditure to boost market
- 10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
- 10.4.2 CHINA
  - 10.4.2.1 Low manufacturing cost and surge in research & development investments to spur growth
- 10.4.3 JAPAN
  - 10.4.3.1 Presence of large geriatric population and increasing research activities to bolster growth
- 10.4.4 INDIA
  - 10.4.4.1 Growing pharmaceutical industry to propel market
- 10.4.5 SOUTH KOREA
  - 10.4.5.1 Ongoing collaborations and research initiatives among market players to encourage growth
- 10.4.6 AUSTRALIA
  - 10.4.6.1 Robust healthcare infrastructure to facilitate growth
- 10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
- 10.5.2 BRAZIL
  - 10.5.2.1 Growing focus on biotechnology and biomedical innovations to drive market
- 10.5.3 MEXICO
  - 10.5.3.1 Low manufacturing cost and large population to support growth
- 10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
- 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST
- 10.6.2 GCC COUNTRIES
  - 10.6.2.1 Saudi Arabia
    - 10.6.2.1.1 Increasing life science research funding to aid growth
  - 10.6.2.2 UAE
    - 10.6.2.2.1 Presence of research institutes supporting live cell imaging studies to foster growth
  - 10.6.2.3 Rest of GCC Countries
- 10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
- 10.7.1 GOVERNMENT INITIATIVES TO CONTRIBUTE TO GROWTH
- 10.7.2 MACROECONOMIC ANALYSIS FOR AFRICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LIVE CELL IMAGING MARKET
11.3 REVENUE ANALYSIS, 2022-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY VALUATION AND FINANCIAL METRICS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 11.7.1 STARS
- 11.7.2 EMERGING LEADERS
- 11.7.3 PERVASIVE PLAYERS
- 11.7.4 PARTICIPANTS
11.8 COMPANY FOOTPRINT, KEY PLAYERS, 2024
- 11.8.1 COMPANY FOOTPRINT
- 11.8.2 REGION FOOTPRINT
- 11.8.3 OFFERING FOOTPRINT
- 11.8.4 APPLICATION FOOTPRINT
11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 11.9.1 PROGRESSIVE COMPANIES
- 11.9.2 RESPONSIVE COMPANIES
- 11.9.3 DYNAMIC COMPANIES
- 11.9.4 STARTING BLOCKS
11.10 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 11.10.1 DETAILED LIST OF KEY STARTUPS/SMES
- 11.10.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
11.11 COMPETITIVE SCENARIO
- 11.11.1 PRODUCT LAUNCHES AND UPGRADES
- 11.11.2 DEALS
- 11.11.3 EXPANSIONS

12 COMPANY PROFILE

12.1 KEY PLAYERS
- 12.1.1 DANAHER
  - 12.1.1.1 Business overview
  - 12.1.1.2 Products offered
  - 12.1.1.3 Recent developments
    - 12.1.1.3.1 Product launches and upgrades
    - 12.1.1.3.2 Deals
  - 12.1.1.4 MnM view
    - 12.1.1.4.1 Key strengths
    - 12.1.1.4.2 Strategic choices
    - 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 ZEISS GROUP
  - 12.1.2.1 Business overview
  - 12.1.2.2 Products offered
  - 12.1.2.3 Recent developments
    - 12.1.2.3.1 Product launches and upgrades
    - 12.1.2.3.2 Deals
    - 12.1.2.3.3 Expansions
  - 12.1.2.4 MnM view
    - 12.1.2.4.1 Key strengths
    - 12.1.2.4.2 Strategic choices
    - 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 THERMO FISHER SCIENTIFIC INC.
  - 12.1.3.1 Business overview
  - 12.1.3.2 Products offered
  - 12.1.3.3 Recent developments
    - 12.1.3.3.1 Deals
  - 12.1.3.4 MnM view
    - 12.1.3.4.1 Key strengths
    - 12.1.3.4.2 Strategic choices
    - 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 REVVITY
  - 12.1.4.1 Business overview
  - 12.1.4.2 Products offered
  - 12.1.4.3 Recent developments
    - 12.1.4.3.1 Product launches and upgrades
  - 12.1.4.4 MnM view
    - 12.1.4.4.1 Key strengths
    - 12.1.4.4.2 Strategic choices
    - 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 SARTORIUS AG
  - 12.1.5.1 Business overview
  - 12.1.5.2 Products offered
  - 12.1.5.3 Recent developments
    - 12.1.5.3.1 Deals
  - 12.1.5.4 MnM view
    - 12.1.5.4.1 Key strength
    - 12.1.5.4.2 Strategic choices
    - 12.1.5.4.3 Weaknesses and competitive threats
- 12.1.6 NIKON CORPORATION
  - 12.1.6.1 Business overview
  - 12.1.6.2 Products offered
  - 12.1.6.3 Recent developments
    - 12.1.6.3.1 Expansions
- 12.1.7 EVIDENT
  - 12.1.7.1 Business overview
  - 12.1.7.2 Products offered
  - 12.1.7.3 Recent developments
    - 12.1.7.3.1 Product launches and upgrades
- 12.1.8 AGILENT TECHNOLOGIES, INC.
  - 12.1.8.1 Business overview
  - 12.1.8.2 Products offered
  - 12.1.8.3 Recent developments
    - 12.1.8.3.1 Product launches and upgrades
- 12.1.9 NANOENTEK
  - 12.1.9.1 Business overview
  - 12.1.9.2 Products offered
- 12.1.10 BRUKER
  - 12.1.10.1 Business overview
  - 12.1.10.2 Products offered
  - 12.1.10.3 Recent developments
    - 12.1.10.3.1 Deals
- 12.1.11 BD
  - 12.1.11.1 Business overview
  - 12.1.11.2 Products offered
- 12.1.12 MERCK KGAA
  - 12.1.12.1 Business overview
  - 12.1.12.2 Products offered
- 12.1.13 BIO-RAD LABORATORIES, INC.
  - 12.1.13.1 Business overview
  - 12.1.13.2 Products offered
- 12.1.14 TECAN TRADING AG
  - 12.1.14.1 Business overview
- 12.1.15 SYSMEX CORPORATION
  - 12.1.15.1 Business overview
  - 12.1.15.2 Products offered
- 12.1.16 CORNING INCORPORATED
  - 12.1.16.1 Business overview
  - 12.1.16.2 Products offered
12.2 OTHER PLAYERS
- 12.2.1 AXION BIOSYSTEMS, INC.
- 12.2.2 BLUE-RAY BIOTECH CORP.
- 12.2.3 CURIOSIS INC.
- 12.2.4 CYTENA GMBH
- 12.2.5 ABBERIOR GMBH
- 12.2.6 PHASE HOLOGRAPHIC IMAGING PHI AB
- 12.2.7 ALIGNED GENETICS INC.
- 12.2.8 CHERRY BIOTECH
- 12.2.9 NANOLIVE SA
- 12.2.10 CYTOTRONICS
- 12.2.11 ETALUMA, INC.
- 12.2.12 TISSUEGNOSTICS GMBH

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS